Abstract
A major goal of cancer chemotherapy is the identification of cytotoxic compounds that are highly selective for cancer cells. We describe here one such compound – a novel iron chelator, desferri-exochelin 772SM. This desferri-exochelin has unique chemical and pharmacological properties, including extremely high iron binding affinity, the capacity to block iron-mediated redox reactions, and lipid solubility which enables it to enter cells rapidly. At low concentrations, this desferri-exochelin kills T47D-YB and MCF-7 human breast cancer cells by inducing apoptosis, but only reversibly arrests the growth of normal human mammary epithelial cells without cytotoxicity. Since iron-loaded exochelin is ineffective, iron chelation accounts for the efficacy of desferri-exochelin. For both the killing of breast cancer cells and the growth arrest of normal breast epithelial cells, desferri-exochelin was effective at much lower concentrations than the lipid-insoluble iron chelator deferoxamine, which has shown only limited potential as an anti-cancer agent. Growth arrest of progesterone receptor positive T47D-YB cells with the progestin R5020 transiently protects them from the cytotoxic effects of desferri-exochelin, but the cells are killed after cell growth resumes. Similarly, MCF-7 cells arrested with the estrogen antagonist ICI182780 are transiently resistant to killing by desferri-exochelin. Thus the desferri-exochelin is cytotoxic only to actively growing tumor cells. Since desferri-exochelin 772SM can selectively and efficiently destroy proliferating cancer cells without damaging normal cells, it may prove useful for the treatment of cancer.
Similar content being viewed by others
References
Richardson DR, Ponka P: The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1331: 1-40, 1997
Becton DL, Roberts B: Antileukemic effects of deferoxamine on human myeloid leukemia cell lines. Cancer Res 49: 4809-4812, 1989
Head JF, Wang F, Elliott RL: Antineoplastic drugs that interfere with iron metabolism in cancer cells. Adv Enzyme Regul 37: 147-169, 1997
Brodie C, Siriwardana G, Lucas J, Schleicher R, Terada N, Szepesi A, Gelfand E, Seligman P: Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res 53: 3968-3975, 1993
Lloyd JB, Cable H, Rice-Evans C: Evidence that desferrioxamine cannot enter cells by passive diffusion. Biochem Pharmacol 41: 1361-1363, 1991
Howland MA: Risks of parenteral deferoxamine for acute iron poisoning. Clin Toxicol 34: 491-497, 1996
Gobin J, Moore CH, Reeve JR, Jr, Wong DK, Gibson BW, Horwitz MA: Iron acquisition by Mycobacterium tuberculosis: isolation and characterization of a family of iron-binding exochelins. Proc Natl Acad Sci USA 92: 5189-5193, 1995
Gobin J, Horwitz MA: Exochelins of Mycobacterium tuberculosis remove iron from human iron-binding proteins and donate iron to mycobactins in the M. tuberculosis cell wall. J Expt Med 183: 1527-1532, 1996
Horwitz LD, Sherman NA, Kong Y, Pike AW, Gobin J, Fennessey PV, Horwitz MA: Lipophilic siderophores of Mycobacterium tuberculosis prevent cardiac reperfusion injury. Proc Natl Acad Sci USA 95: 5263-5268, 1998
Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS, Horwitz KB: New T47D breast cancer cell lines for the independent study of progesterone B-and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 54: 3868-3877, 1994
Soule HD, Vazguez J, Long A, Albert S, Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1416, 1973
Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, Sclafani RA, Lange CA, Horwitz KB: Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27Kip1. Mol Endocrinol 11: 1593-1607, 1997
Watts CKW, Brady A, Sarcevic B, deFazio A, Musgrove EA, Sutherland RL: Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 9: 1804-1813, 1995
Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867-3873, 1991
Jordan A, Reichard P: Ribonucleotide reductases. Annu Rev Biochem 67: 71-98, 1998
Boldt DH: New perspectives on iron: an introduction. Am J Med Sci 318: 207-212, 1999
Brenneisen P, Wenk J, Klotz LO, Wlaschek M, Briviba K, Krieg T, Sies H, Scharffetter-Kochanek K: Central role of Ferrous/Ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts. J Biol Chem 273: 5279-5287, 1998
Shterman N, Kupfer B, Moroz C: Comparison of transferrin receptors, iron content and isoferritin profile in normal and malignant human breast cell lines. Pathobiology 59: 19-25, 1991
Cavanaugh PG, Nicolson GL: Selection of highly metastatic rat MTLn2 mammary adenocarcinoma cell variants using in vitro growth response to transferrin. J Cell Physiol 174: 48-57, 1998
Inoue T, Cavanaugh PG, Steck PA, Nicolson GL: Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol 156: 212-217, 1993
Weinstein RE, Bond BH, Silberberg BK: Tissue ferritin concentration in carcinoma of the breast. Cancer 50: 2406-2409, 1982
Weinstein RE, Bond BH, Silberg BK, Vaughn CB, Subbaiah P, Pieper DR: Tissue ferritin concentration and prognosis in carcinoma of the breast. Breast Cancer Res Treat 14: 349-353, 1989
Hann H-WL, Stahlhut MW, Blumberg BS: Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res 48: 4168-4170, 1988
Hann H-WL, Stahlhut MW, Menduke H: Iron enhances tumor growth. Cancer 68: 2407-2410, 1991
Hann HWL, Stahlhut MW, Rubin R, Maddrey WC: Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 70: 2051-2056, 1992
Selig RA, White L, Gramacho C, Sterling-Levis K, Fraser IW, Naidoo D: Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer Res 58: 473-478, 1998
Blatt J, Boegel F, Hedlund BE, Arena VC, Shadduck RK: Failure to alter the course of acute myelogenous leukemia in the rat with subcutaneous deferoxamine. Leuk Res 15: 391-394, 1998
Dreicer R, Kemp JD, Stegink LD, Cardillo T, Davis CS, Forest PK, See WA: A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer. Cancer Invest 15: 311-317, 1997
Pahl PM, Yan XD, Hodges YK, Rosenthal EA, Horwitz MA, Horwitz LD: An exochelin of Mycobacterium tuberculosis reversibly arrests growth of human vascular smooth muscle cells in vitro. J Biol Chem 275: 17821-17826, 2000
Fukuchi K, Tomoyasu S, Tsuruoka N, Gomi K: Iron deprivation-induced apoptosis in HL-60 cells. FEBS Lett 350: 139-142, 1994
Ul-Haq R, Werely JP, Chitambar CR: Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp Hematol 23: 428-432, 1995
Green DR, Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998
Elledge SJ: Cell cycle checkpoints: preventing an identity crisis. Science 274: 1664-1672, 1996
Terada N, Lucas JJ, Gelfand EW: Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb) and p53, during cell cycle progression of normal human T cells. J Immunol 147: 698-704, 1991
Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996
Albanell J, Baselga J: The ErbB receptors as targets for breast cancer therapy. J Mamm Gland Biol Neoplas 4: 337-351, 1999
Sikic BI: New approaches in cancer treatment. Ann Oncol 10(Suppl 6): 149-153, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pahl, P.M., Horwitz, M.A., Horwitz, K.B. et al. Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells. Breast Cancer Res Treat 69, 69–79 (2001). https://doi.org/10.1023/A:1012211828319
Issue Date:
DOI: https://doi.org/10.1023/A:1012211828319